Allogeneic thyTreg cells

N/A

Report date: 2024/07/04 20:00:24

Base Information

Drug NameAllogeneic thyTreg cells

Drug Alias NameTreg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)Allogenic Administration of Treg Cells Obtained From Thymic Tissue (thyTreg)Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg)

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TregsCell and gene therapy > Cell therapy > Source of cells > Thymus-derived

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsSystemic Inflammatory Response Syndrome

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesHospital General Universitario Gregorio Maranon Instituto De Salud Carlos Iii

China Registration ClassN/A

Develop Information

Active CompaniesHospital General Universitario Gregorio Maranon Instituto De Salud Carlos Iii

Inactive CompaniesN/A

Active IndicationsSystemic Inflammatory Response Syndrome

Inactive IndicationsN/A

Other Information

ATC CodeN/A